Robbins LLP Calls for RGC Investors to Join Class Action Against Regencell Bioscience Following Losses

On May 5, 2026, Robbins LLP announced a class action lawsuit for investors who incurred losses from purchasing securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) within the designated class period, which spans from October 28, 2024, to October 31, 2025. The firm is actively urging affected stockholders to reach out for crucial information regarding the class action.

Background on Regencell Bioscience

Regencell Bioscience Holdings Limited is an early-stage company that ventures into the realm of traditional Chinese medicine (TCM) focusing on researching and commercializing treatments for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). The company primarily aims to innovate through the integration of TCM with modern practices.

Unfortunately, the company's journey since its inception has faced challenges, which were magnified during this specific timeframe due to alleged market manipulations impacting the company's share value. Allegations state that during this period, the company's executives made misleading statements and omitted important disclosures about Regencell's vulnerability to stock manipulations, thereby exposing investors to significant financial risks.

Allegations of Misconduct

The class action claims that Regencell was subject to a stock manipulation scheme. Depending on the facts, it is alleged that necessary disclosures about the potential for regulatory scrutiny and its implications for shareholders were not made. The investors suffered losses which escalated upon the announcement of a U.S. Department of Justice (DOJ) investigation into Regencell. The turmoil reached a peak when, on October 31, 2025, the company revealed it was under investigation, leading to a drastic share price drop of 18.56%, falling to $13.56 per share by November 3, 2025.

What Can Shareholders Do?

Shareholders who sustained losses during the specified class period may be eligible to participate in this class action against Regencell Bioscience Holdings Limited. Those interested in leading the case must submit their paperwork to the court by June 23, 2026. It is crucial for potential lead plaintiffs to understand that this role involves representing the interests of all class members in managing the litigation process. However, investors can also choose not to take action and still remain part of the class, allowing for potential recovery without direct involvement in the case.

Robbins LLP emphasizes that its legal representation operates on a contingency basis, meaning that shareholders will incur no fees or expenses unless the case results in a recovery.

About Robbins LLP

Robbins LLP has been a prominent player in the field of shareholder litigation since 2002, focusing on reclaiming losses for shareholders and enhancing corporate governance standards. With a mission to keep company executives accountable, the firm continues to advocate for shareholders in various classes of litigation.

For individuals who want to stay informed about the class action or receive alerts regarding wrongdoing by corporate executives, signing up for Stock Watch is highly recommended. This service provides up-to-date notifications about settlements and legal matters involving publicly-held companies.

In a landscape where financial misconduct can have devastating impacts on investors, staying informed and connected to legal resources like Robbins LLP is a wise decision. For personalized support or further inquiries, impacted investors can fill out a form, reach out to attorney Aaron Dumas, Jr. directly, or call the firm at (800) 350-6003.

By promoting collective legal action, Robbins LLP aims to create a more secure and transparent investment environment for all shareholders involved.